Dresner Partners drives Therafin Corporation partnership with AltimateMedical

In Chicago, on April 30, 2025, Dresner Partners, a FINRA-registered middle-market investment bank, announced its advisory role in forming a partnership between Therafin Corporation and AltimateMedical. This strategic move aims to enhance product offerings and market reach in the rehabilitation and healthcare sectors. Therafin President Todd Fink expressed enthusiasm about the collaboration, highlighting the long-standing relationship with Dresner Partners and the importance of maintaining the company's legacy. Dresner executives emphasized the partnership's potential to create stakeholder value, reflecting their commitment to supporting middle-market companies and facilitating growth initiatives. The partnership with AltimateMedical, known for its ties to Granite Partners, is a significant step towards expanding the capacities of Therafin Corporation, a company deeply rooted in the rehabilitation industry. Todd Fink also mentioned that this collaboration aligns with the foundational values instilled by his father, reinforcing the company's dedication to its customers and team. By leveraging the strengths of both companies, they aim to broaden their combined market influence and enhance service offerings, driven by shared objectives in the healthcare sector. Dresner Partners has garnered a reputation for providing essential advisory services, especially in mergers and acquisitions. Steven M. Dresner, President of Dresner Partners, expressed satisfaction with facilitating this strategic partnership, affirming the longstanding relationships they maintain with clients like Therafin Corporation. The firm's commitment to enhance stakeholder value aligns with their strategic advisory services, showcasing the impact of effective collaboration in enhancing growth opportunities for middle-market entities. The announcement highlights the ongoing trends in the rehabilitation and healthcare markets, as companies seek partnerships to enhance their competitive edge and operational efficiencies. The partnership is seen as crucial given the evolving landscape of healthcare, where innovation and comprehensive product lines can significantly improve service delivery. As Therafin Corporation embarks on this new phase of growth, industry observers will be keenly watching to see how this collaboration unfolds and its resultant impact on the healthcare market.